cyclophosphamide/pentostatin/rituximab (PCR regimen)
Jump to navigation
Jump to search
Indications
- chronic lymphocytic leukemia (91% response rate)
Dosage
6 21 day cycles of:
- pentostatin 2 mg/m2
- cyclophosphamide 600 mg/m2
- rituximab 375 mg/m2
- rituximab administer 3X in 1st week of 1st cycle only
- filgrastim administered with each cycle
Adverse effects
- pancytopenia (34%)
- infections (2%)
- death uncommon
More general terms
Components
- pentostatin (Nipent, DCF, 2'deoxycoformycin)
- cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]
- rituximab (Rituxan, Mabthera, Truxima, Ruxience, Riabni)
References
- ↑ Kay NE et al, Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007, 109:405 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17008537